pharmaceutical
5 cases — ← All topics
| Case | Title | Lower Court | Docketed | Status | Flags | Tags | Question Presented |
|---|---|---|---|---|---|---|---|
| 25A587 | Novartis Pharmaceuticals Corporation v. Robert F. Kennedy, Secretary of Health and Human Services, et al. | Third Circuit | 2025-11-18 | Application | certiorari consumer-protection extension pharmaceutical regulatory time-limit | Whether the Supreme Court should grant a pharmaceutical company an extension of time to file a petition for certiorari in a case involving significant… | |
| 19-584 | Nuvo Pharmaceuticals (Ireland) Designated Activity Company, et al. v. Dr. Reddy's Laboratories Inc., et al. | Federal Circuit | 2019-11-04 | Denied | Response Waived | 35-usc-112 enablement federal-circuit innovation patent patent-law pharmaceutical pharmaceutical-composition prior-art written-description | Whether the Federal Circuit erred by holding that, whenever the prior art teaches away from a pharmaceutical composition, the written description of a… |
| 18-1502 | Brian Mark Burmaster v. Eli Lilly and Company | Sixth Circuit | 2019-06-03 | Denied | 6th-amendment civil-rights constitutional-rights drug-marketing due-process free-speech government-action government-intervention government-overreach government-regulation medical-ethics pharmaceutical pharmaceutical-liability pharmaceutical-litigation sixth-amendment | If a company's manufactured and marketed product is cited by the US Government as a 'miracle drug' to restore a criminal defendant's Sixth Amendment r… | |
| 18-441 | Accord Healthcare, Inc., et al. v. UCB, Inc., et al. | Federal Circuit | 2018-10-09 | Denied | Amici (1)Response Waived | 35-usc-103 lead-compound obviousness patent patent-invalidation patent-law pharmaceutical pharmaceutical-compound prior-art | Whether the Federal Circuit erred in holding that a patent claim to an obvious modification of a prior art compound was not invalid as obvious under 3… |
| 18-182 | AIDS Healthcare Foundation, Inc. v. Gilead Sciences, Inc., et al. | Federal Circuit | 2018-08-09 | Denied | Response Waived | actual-controversy article-iii declaratory-judgment drug-exclusivity fda-approval generic-drugs patent-invalidity pharmaceutical pharmaceutical-patents standing | Whether the 'actual controversy' requirement of the Declaratory Judgment Act requires a party seeking to introduce a generic drug product to file an a… |